

```
[et_pb_section bb_built="1" fullwidth="on" specialty="off" transparent_background="off"
allow_player_pause="off" inner_shadow="off" parallax="off" parallax_method="off"
make_fullwidth="off" use_custom_width="off" width_unit="on" make_equal="off"
use_custom_gutter="off"] [et_pb_fullwidth_header background_layout="light"
text_orientation="left" header_fullscreen="off" header_scroll_down="off"
background_url="http://www.flatleydiscoverylab.com/wp-content/uploads/2017/05/AdobeStock_112123671_Preview.jpeg" background_color="#f5f1e3" content_orientation="center"
image_orientation="center" custom_button_one="off" button_one_letter_spacing="0"
button_one_icon_placement="right" button_one_letter_spacing_hover="0"
custom_button_two="off" button_two_letter_spacing="0"
button_two_icon_placement="right" button_two_letter_spacing_hover="0"
custom_css_main_element="padding: 120px 0px;"
background_overlay_color="rgba(245,241,227,0)" module_class="gradient-overlay"
_builder_version="3.0.62"
background_image="http://www.flatleydiscoverylab.com/wp-content/uploads/2017/07/FDL31.jpg" /] [et_pb_section bb_built="1" fullwidth="off" specialty="on"
parallax_method="off" parallax_method_1="off" parallax_method_2="off"
module_class_2="sidebar" _builder_version="3.0.62" background_position_1="top_left"
background_repeat_1="no-repeat" background_position_2="top_left"
background_repeat_2="no-repeat" custom_padding="25px|||"
padding_top_2="0px" ] [et_pb_column type="3_4" specialty_columns="3" ] [et_pb_row_inner
admin_label="Row" ] [et_pb_column_inner type="4_4"
saved_specialty_column_type="3_4" ] [et_pb_text admin_label="Heading"
_builder_version="3.0.62" background_layout="light" text_orientation="left"
border_style="solid" saved_tabs="all" ]
```

FDL169 a CFTR Corrector

```
[/et_pb_text] [et_pb_text _builder_version="3.0.62" background_layout="light"
text_orientation="left" border_style="solid" ]
```

FDL169 Phase 1b Study

FDL169-2016-04 Study is a randomized, double-blind, placebo-controlled, parallel study to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FDL169 in cystic

fibrosis subjects homozygous for the F508del-CFTR mutation.

Enrollment is planned to occur at approximately 14 global sites. Approximately 24 adults with CF will be enrolled in the study. Participation in this study will take approximately 9 weeks.

Requirements for participation in the study:

- A diagnosis of cystic fibrosis
- Have 2 copies of the F508del-CFTR mutation
- Be 18 years of age or older
- Have a weight ≥ 40 kg
- Have an FEV1 $\geq 40\%$ predicted
- No respiratory tract infection, pulmonary exacerbation, or changes in therapy for pulmonary disease 4 weeks prior to dosing
- No treatment with ivacaftor or lumacaftor 4 weeks prior to dosing

Additional information is available at www.clinicaltrials.gov

```
[/et_pb_text][/et_pb_column_inner][/et_pb_row_inner][/et_pb_column][et_pb_column
type="1_4"][et_pb_sidebar_builder_version="3.0.62" area="et_pb_widget_area_2"
orientation="right" background_layout="light" ][et_pb_button admin_label="Make a
Difference Button" button_url="/volunteer-opportunities/" url_new_window="off"
button_text="Make a Difference" button_alignment="center" background_layout="dark"
custom_button="on" button_bg_color="#63ccca" button_border_color="#63ccca"
button_letter_spacing="0" button_icon="%%141%%" button_icon_color="#ffffff"
button_icon_placement="right" button_letter_spacing_hover="0"
custom_css_main_element="width: 100%;" button_border_radius="0" saved_tabs="all"
_builder_version="3.0.62" ][/et_pb_column][et_pb_section][et_pb_section bb_built="1"
fullwidth="off" specialty="off" background_color="#0074bc" parallax_method="off"
_builder_version="3.0.62"][et_pb_row][et_pb_column type="4_4"][et_pb_blurb
admin_label="Structure icon" url_new_window="off" use_icon="off" use_circle="off"
use_circle_border="off"
image="http://www.flatleydiscoverylab.com/wp-content/uploads/2017/07/polygon-molecule-
white.png" icon_placement="top" animation="top" background_layout="light"
max_width="100px" use_icon_font_size="off" border_style="solid"
background_position="top_left" background_repeat="repeat" background_size="initial"
```

```
_builder_version="3.0.62" /][et_pb_cta admin_label="Have an Idea?" title="Have an Idea?"  
button_url="/ideas/" url_new_window="off" button_text="Submit an Idea"  
use_background_color="off" background_layout="dark" border_style="solid"  
custom_button="on" button_text_color="#ffffff" button_bg_color="#63ccca"  
button_border_color="#63ccca" button_letter_spacing="0" button_icon_placement="right"  
button_letter_spacing_hover="0" background_position="top_left"  
background_repeat="repeat" background_size="initial" _builder_version="3.0.62"]
```

We'd love to hear it!

```
[/et_pb_cta][[/et_pb_column][[/et_pb_row][[/et_pb_section]
```